Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer
Open Access
- 13 August 2022
- journal article
- research article
- Published by Elsevier BV in Value in Health
- Vol. 26 (1), 71-80
- https://doi.org/10.1016/j.jval.2022.07.006
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencingLung Cancer, 2016
- Clinical next‐generation sequencing in patients with non–small cell lung cancerCancer, 2014
- Estimating Multiparameter Partial Expected Value of Perfect Information from a Probabilistic Sensitivity Analysis SampleMedical Decision Making, 2013
- Model Parameter Estimation and Uncertainty AnalysisMedical Decision Making, 2012
- Scenario drafting to anticipate future developments in technology assessmentBMC Research Notes, 2012
- Implementation by simulation; strategies for ultrasound screening for hip dysplasia in the NetherlandsBMC Health Services Research, 2010
- The Economic Value of Innovative Treatments over the Product Life Cycle: The Case of Targeted Trastuzumab Therapy for Breast CancerValue in Health, 2009
- Review on early technology assessments of nanotechnologies in oncologyMolecular Oncology, 2009
- Scenario Planning: a Tool for Conservation in an Uncertain WorldConservation Biology, 2003
- A rational framework for decision making by the National Institute For Clinical Excellence (NICE)The Lancet, 2002